Achilles Therapeutics
ACHL
ACHL was delisted on the 20th of March, 2025.
29 hedge funds and large institutions have $278M invested in Achilles Therapeutics in 2021 Q1 according to their latest regulatory filings, with 29 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
41.39% more ownership
Funds ownership: 0% → 41.39% (+41%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$42.9M |
| 2 |
AG
Artal Group
Luxembourg
|
+$37.3M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$34.6M |
| 4 |
O
OrbiMed
New York
|
+$26.2M |
| 5 |
BC
Boxer Capital
San Diego,
California
|
+$25.4M |
Top Sellers
ACHL Hedge Fund Activity: Q1 2021 in Review
29 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Achilles Therapeutics (ACHL) for Q1 2021, worth a combined $278M.
Buyers outnumbered sellers: 29 funds opened new ACHL positions and 0 closed out — a net gain of 29 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $42.9M.
- 29 institutional investors held Achilles Therapeutics (ACHL) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $278M of Achilles Therapeutics stock for Q1 2021.
- 29 funds opened new Achilles Therapeutics positions in Q1 2021 and 0 closed out, a net change of +29 holders.
- The largest Achilles Therapeutics buyer in Q1 2021 was Baker Bros. Advisors, an estimated $42.9M added.
Based on aggregated 13F filings for Q1 2021.